Compare · CRL vs NOTV
CRL vs NOTV
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and Inotiv Inc. (NOTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and NOTV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $8.73B, about 1507.3x NOTV ($5.8M).
- Over the past year, CRL is up 23.0% and NOTV is down 94.6% - CRL leads by 117.6 points.
- CRL has been more active in the news (17 items in the past 4 weeks vs 6 for NOTV).
- CRL has more recent analyst coverage (25 ratings vs 9 for NOTV).
- Company
- Charles River Laboratories International Inc.
- Inotiv Inc.
- Price
- $181.33-2.43%
- $0.16+88.77%
- Market cap
- $8.73B
- $5.8M
- 1M return
- -0.16%
- -46.70%
- 1Y return
- +22.97%
- -94.58%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 17
- 6
- Recent ratings
- 25
- 9
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Inotiv Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Latest CRL
- Director Barg Steven was granted 422 shares, increasing direct ownership by 15% to 3,287 units (SEC Form 4)
- EVP & Chief Financial Officer Coleman Glenn was granted 6,640 shares, increasing direct ownership by 31% to 27,752 units (SEC Form 4)
- EVP, Chief Information Officer Mintz Mark was granted 2,534 shares and covered exercise/tax liability with 369 shares, increasing direct ownership by 29% to 9,546 units (SEC Form 4)
- EVP, Corp Strategy & Develop Laplume Joseph W was granted 5,257 shares and covered exercise/tax liability with 979 shares, increasing direct ownership by 16% to 31,298 units (SEC Form 4)
- SVP, Finance and CAO Knell Michael Gunnar was granted 1,837 shares and covered exercise/tax liability with 200 shares, increasing direct ownership by 11% to 16,152 units (SEC Form 4)
- Chief Executive Officer Girshick Birgit was granted 9,961 shares and covered exercise/tax liability with 1,582 shares, increasing direct ownership by 27% to 39,399 units (SEC Form 4)
- Director Foster James C covered exercise/tax liability with 1,596 shares, decreasing direct ownership by 0.57% to 279,957 units (SEC Form 4)
- EVP & Chief People Officer Creamer Victoria L was granted 5,135 shares and covered exercise/tax liability with 810 shares, increasing direct ownership by 17% to 30,051 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M was granted 4,361 shares and covered exercise/tax liability with 721 shares, increasing direct ownership by 47% to 11,382 units (SEC Form 4)
- Charles River Laboratories to Present at William Blair and Jefferies Conferences
Latest NOTV
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Young John T. Jr.
- SEC Form 3 filed by new insider Davis Eugene I
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Leadership Update, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 10-Q filed by Inotiv Inc.
- Inotiv Inc. filed SEC Form 8-K: Other Events
- Inotiv Inc. filed SEC Form 8-K: Other Events
- Inotiv Inc. filed SEC Form 8-K: Other Events